CRISPR THERAPEUTICS AG (CRSP)

CH0334081137 - Common Stock

40.94  +0.46 (+1.14%)

After market: 40.9694 +0.03 (+0.07%)

Fundamental Rating

4

We assign a fundamental rating of 4 out of 10 to CRSP. CRSP was compared to 565 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for CRSP as it has an excellent financial health rating, but there are worries on the profitability. CRSP shows excellent growth, but is valued quite expensive already.



Quickly go to:

2

1. Profitability

1.1 Basic Checks

CRSP had negative earnings in the past year.
CRSP had a negative operating cash flow in the past year.
In multiple years CRSP reported negative net income over the last 5 years.
The reported operating cash flow has been mixed in the past 5 years: CRSP reported negative operating cash flow in multiple years.

1.2 Ratios

CRSP has a better Return On Assets (-10.62%) than 87.01% of its industry peers.
CRSP's Return On Equity of -12.35% is amongst the best of the industry. CRSP outperforms 89.68% of its industry peers.
Industry RankSector Rank
ROA -10.62%
ROE -12.35%
ROIC N/A
ROA(3y)-7.38%
ROA(5y)-6.99%
ROE(3y)-9.03%
ROE(5y)-8.19%
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for CRSP so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

More info and screens

8

2. Health

2.1 Basic Checks

CRSP does not have a ROIC to compare to the WACC, probably because it is not profitable.
CRSP has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, CRSP has more shares outstanding
There is no outstanding debt for CRSP. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

2.2 Solvency

An Altman-Z score of 6.39 indicates that CRSP is not in any danger for bankruptcy at the moment.
CRSP's Altman-Z score of 6.39 is amongst the best of the industry. CRSP outperforms 83.10% of its industry peers.
CRSP has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 6.39
ROIC/WACCN/A
WACC4.93%

2.3 Liquidity

A Current Ratio of 21.64 indicates that CRSP has no problem at all paying its short term obligations.
With an excellent Current ratio value of 21.64, CRSP belongs to the best of the industry, outperforming 95.73% of the companies in the same industry.
A Quick Ratio of 21.64 indicates that CRSP has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 21.64, CRSP belongs to the top of the industry, outperforming 95.73% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 21.64
Quick Ratio 21.64

More info and screens

7

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 36.69% over the past year.
The Revenue has grown by 19.31% in the past year. This is quite good.
The Revenue has been growing by 160.41% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)36.69%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%28.37%
Revenue 1Y (TTM)19.31%
Revenue growth 3Y709.42%
Revenue growth 5Y160.41%
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, CRSP will show a very strong growth in Earnings Per Share. The EPS will grow by 27.68% on average per year.
Based on estimates for the next years, CRSP will show a very strong growth in Revenue. The Revenue will grow by 38.43% on average per year.
EPS Next Y-168.27%
EPS Next 2Y-61.65%
EPS Next 3Y-17.51%
EPS Next 5Y27.68%
Revenue Next Year-94.75%
Revenue Next 2Y-32.42%
Revenue Next 3Y31.42%
Revenue Next 5Y38.43%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CRSP. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CRSP. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

A cheap valuation may be justified as CRSP's earnings are expected to decrease with -17.51% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-61.65%
EPS Next 3Y-17.51%

More info and screens

0

5. Dividend

5.1 Amount

CRSP does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CRISPR THERAPEUTICS AG

NASDAQ:CRSP (12/24/2024, 8:04:59 PM)

After market: 40.9694 +0.03 (+0.07%)

40.94

+0.46 (+1.14%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-05 2024-11-05/bmo
Earnings (Next)02-17 2025-02-17/amc
Inst Owners71.32%
Inst Owner Change0.98%
Ins Owners1.67%
Ins Owner Change-0.82%
Market Cap3.49B
Analysts73.71
Price Target81.64 (99.41%)
Short Float %21.63%
Short Ratio11.2
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)17.23%
Min EPS beat(2)4.06%
Max EPS beat(2)30.41%
EPS beat(4)3
Avg EPS beat(4)405.58%
Min EPS beat(4)-5.19%
Max EPS beat(4)1593.05%
EPS beat(8)7
Avg EPS beat(8)225.92%
EPS beat(12)8
Avg EPS beat(12)148.87%
EPS beat(16)10
Avg EPS beat(16)121.24%
Revenue beat(2)0
Avg Revenue beat(2)-88.5%
Min Revenue beat(2)-91.33%
Max Revenue beat(2)-85.67%
Revenue beat(4)1
Avg Revenue beat(4)-56.32%
Min Revenue beat(4)-98.14%
Max Revenue beat(4)49.85%
Revenue beat(8)3
Avg Revenue beat(8)477.46%
Revenue beat(12)4
Avg Revenue beat(12)335.31%
Revenue beat(16)5
Avg Revenue beat(16)247.71%
PT rev (1m)-1.08%
PT rev (3m)-1.44%
EPS NQ rev (1m)0%
EPS NQ rev (3m)6.33%
EPS NY rev (1m)0%
EPS NY rev (3m)10.45%
Revenue NQ rev (1m)-4.26%
Revenue NQ rev (3m)-81.39%
Revenue NY rev (1m)-36.38%
Revenue NY rev (3m)-68.46%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 17.23
P/FCF N/A
P/OCF N/A
P/B 1.8
P/tB 1.8
EV/EBITDA N/A
EPS(TTM)-2.83
EYN/A
EPS(NY)-5.12
Fwd EYN/A
FCF(TTM)-2.24
FCFYN/A
OCF(TTM)-2.21
OCFYN/A
SpS2.38
BVpS22.73
TBVpS22.73
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -10.62%
ROE -12.35%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-7.38%
ROA(5y)-6.99%
ROE(3y)-9.03%
ROE(5y)-8.19%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.09
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 12.49%
Cap/Sales 1.19%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 21.64
Quick Ratio 21.64
Altman-Z 6.39
F-Score6
WACC4.93%
ROIC/WACCN/A
Cap/Depr(3y)222.65%
Cap/Depr(5y)202.1%
Cap/Sales(3y)1037.38%
Cap/Sales(5y)1148.61%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)36.69%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%28.37%
EPS Next Y-168.27%
EPS Next 2Y-61.65%
EPS Next 3Y-17.51%
EPS Next 5Y27.68%
Revenue 1Y (TTM)19.31%
Revenue growth 3Y709.42%
Revenue growth 5Y160.41%
Sales Q2Q%N/A
Revenue Next Year-94.75%
Revenue Next 2Y-32.42%
Revenue Next 3Y31.42%
Revenue Next 5Y38.43%
EBIT growth 1Y21.53%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-47.8%
EBIT Next 3Y-7.13%
EBIT Next 5Y16.04%
FCF growth 1Y62.4%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y59.69%
OCF growth 3YN/A
OCF growth 5YN/A